The Group Managing Director of Emzor Pharmaceutical Industries Ltd and Emzor Group, Dr. Stella Chinyelu Okoli (OON.) was conferred with the Silverbird Lifetime Achievement Award on Friday the 23rd of February, 2018. The Illustrious Nigerian Industrialist and Business Mogul was bestowed with the award for her most profound achievements and contribution in the advancement of the Nigerian Economy. The event which took place at the Eko Hotel and Suites Victoria Island, Lagos was graced with a notable number of dignitaries.
2018 started off on an exciting note as Emzor’s Brand Ambassador, Asisat Oshoala won the AITEO CAF African Women’s Footballer of the Year for the second time in a row, making it her third.
To celebrate this accomplishment, Emzor Pharmaceuticals organised a reception tagged “Emzor & Asisat- A Winning Team.” Which held at the Ambassadors Hotel, Ikoyi, Lagos .
In attendance were Dr Stella C. Okoli, OON, Founder/Group Managing Director; Mr Emeka Okoli, Chairman; Mrs Uzoma Ezeoke, Executive Director, General Duties (HR & Finance) and Mrs Stella-maris Nwaozuzu. Also present was Mr. Muyiwa Kayode Managing Director of USP Brand Management.
Several media houses were present, including The Guardian, Complete Sports, The Punch, Brilla FM and TVC to mention a few.
To wrap up the event Asisat expressed her gratitude to the Emzor family for their unwavering support and has promised to represent the brand in the best ways possible.
Despite technological advancements even in the medical field, Malaria remains a cause for concern as it is still the number one killer disease in sub-Saharan Africa and number two in the world.
In 2015 alone there were 214 million cases of malaria and 438 000 deaths. Sub-Saharan Africa was home to 88% of these malaria cases and 90% of malaria deaths. (WHO December 2015)
Various measures to prevent and control malaria have been taken, yet the prevalence of malaria incidents is still a major cause for concern. The need for effective treatment of malaria is therefore inevitable.
Over the years, Emzor Pharmaceutical Industries Ltd, has been actively involved in combating malaria through the Manufacturing and distribution of high quality antimalarials like Chloroquine and Sulphadoxine/ Pyrimethamine (Maldox) and in more recent times, the WHO recommended Artemisinin based Combination Therapy (ACT).
In 2009, Emzor launched LOKMAL, her brand of Artemether/ Lumefantrine, which at that time was the first locally manufactured Artemether/ Lumefantrine in the Nigerian Pharmaceutical market. Artemether/ Lumefantrine also happens to be the first choice ACT in Nigeria currently, owing to its high efficacy and excellent safety profile in all classes of patients.
Driven by the vision and philosophy of making unlimited wellness available to all and affordable by all, Emzor has invested immensely in the production and distribution of Lokmal to combat Malaria Nationwide and even beyond the shores of Nigeria, with offices and distribution networks extending to Liberia and Sierra Leone.
Lokmal is manufactured locally here in Nigeria. A proudly Nigerian product with certified quality and manufactured according to internationally recognized GMP. It is a convenient, easy to take antimalarial for the treatment of acute, uncomplicated malaria infection.
One of the challenges faced in effective treatment of malaria is non-adherence/ non-compliance of patients to dosage regimen. This non-compliance could be due to several reasons including, high pill burden and frequency of administration which results into patients omitting doses, taking less medication than is prescribed or discontinuing medication prematurely. This generally results in reduced effectiveness of drugs, treatment failure and higher cost of therapy.
Measures that can be taken to improve patient adherence and compliance include, Improving patient education, Simplifying medication regimen i.e fewer drugs , fewer dose, Simplifying medication package, effective medication reminders and reducing the pill burden.
This has led to the production of LokmalQS combi. LokmalQS combi is a co-pack of higher strength with a fixed dose combination of Artemether/Lumefantrine (80mg/480mg) and our flagship analgesic Emzor Paracetamol tablet (500mg).
This packaging will help patients to always remember to take Paracetamol whenever they are treating malaria and will result in quick resolution of fever, headaches and pains during the course of malaria treatment.
The added value of this packaging lies in the fact that the paracetamol is coming to the patient at no additional cost.
Hence the unique selling proposition for LokmalQS combi are, convenience, enhanced compliance and cost effectiveness.
By Pharm. Gbenga Obaparusi
Emzor Marketing and Sales team’s presence was felt at the 2017 ACPN 36th Annual National Conference held in Jos. The Theme for this year’s conference was: “COMMUNITY PHARMACISTS ROLE IN NATION BUILDING: PAST, PRESENT AND FUTURE.” The company showcased its line of new products like: Emzor Para-1000, Lokmal Combi, Kezitil Suspension, Zemeth, Emxidine, and Emmox DT. Our Stand was graced with the presence of a notable number of Healthcare professionals, pharmaceutical scientists, researchers, investors and other dignitaries to mention a few.
Emzor Pharmaceutical Industries Limited joined the rest of the world on the 28th day of April, 2017 to celebrate the World Day for Safety and Health at Work with the theme ‘Optimize the Collection and use of OSH Data.
The event was an occasion to benefit from lectures on the theme, transport road safety and meningitis. The occasion was well attended by representatives from Federal Road Safety Corps , Federal Ministry of Labour and Employment [FMLE] and members of staff. While presentations were made by Dr C.O Okoroafor, Asst. Director from FMLE, Dapo Omolade of Hybrid consulting, Joshua Mogbo of JEM Safety Solutions and Ogochukwu Doris Ayika, a public health professional from Zolon health care limited.
The second successful observance of this event was an evident demonstration of the management’s commitment to the health and safety as well as training of its workforce
Lokmal is our fixed-dose combination antimalarial containing artemether and Lumefantrine, effective in the treatment of acute uncomplicated malaria infections due to Plasmodium Falciparum.
Lokmal comes in several dosage forms which include;
LOKMAL QS (Artemether 80mg + Lumefantrine 480mg per caplet) 1×6
LOKMAL Junior (Artemether 20mg + Lumefantrine 120mg per tablet) 1×24
LOKMAL Oral Paediatric Suspension (Artemether 180mg + Lumefantrine 1080mg) in 60ml bottle